Helmut Forstbauer
GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer.
Möbus V, Lück H, Ladda E, Klare P, Engels K, Schmidt M, Schneeweiss A, Grischke E, Wachsmann G, Forstbauer H, Untch M, Marme F, Blohmer J, Jackisch C, Huober J, Stickeler E, Reinisch M, Link T, Sinn B, Janni W, Denkert C, Seiler S, Solbach C, Schmatloch S, Rey J, Loibl S. GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer. NPJ Breast Cancer 2024; 10:66.
Jul 30, 2024GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer.
Jul 30, 2024NPJ Breast Cancer 2024; 10:66
Möbus Volker, Lück Hans-Joachim, Ladda Ekkehart, Klare Peter, Engels Knut, Schmidt Marcus, Schneeweiss Andreas, Grischke Eva-Maria, Wachsmann Grischa, Forstbauer Helmut, Untch Michael, Marme Frederik, Blohmer Jens-Uwe, Jackisch Christian, Huober Jens, Stickeler Elmar, Reinisch Mattea, Link Theresa, Sinn Bruno Valentin, Janni Wolfgang, Denkert Carsten, Seiler Sabine, Solbach Christine, Schmatloch Sabine, Rey Julia, Loibl Sibylle
MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients
Huebner H, Tesch H, Brucker S, Blohmer J, Fehm T, Heinrich G, Rezai M, Beckmann M, Fasching P, Janni W, Schneeweiss A, Nabieva N, Jückstock J, Häberle L, Müller V, Schrader I, Lorenz R, Forstbauer H, Fink V, Schochter F, Bekes I, Mahner S, Rack B. MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. Cancers (Basel) 2022; 14
Mar 28, 2022MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients
Mar 28, 2022Cancers (Basel) 2022; 14
Huebner Hanna, Tesch Hans, Brucker Sara Y, Blohmer Jens-Uwe, Fehm Tanja N, Heinrich Georg, Rezai Mahdi, Beckmann Matthias W, Fasching Peter A, Janni Wolfgang, Schneeweiss Andreas, Nabieva Naiba, Jückstock Julia, Häberle Lothar, Müller Volkmar, Schrader Iris, Lorenz Ralf, Forstbauer Helmut, Fink Visnja, Schochter Fabienne, Bekes Inga, Mahner Sven, Rack Brigitte
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)
Möbus V, Reinisch M, Link T, Sinn B, Janni W, Denkert C, Furlanetto J, Engels K, Solbach C, Schmatloch S, Rey J, Burchardi N, Loibl S, Stickeler E, Huober J, Lück H, Ladda E, Klare P, Schmidt M, Schneeweiss A, Grischke E, Wachsmann G, Forstbauer H, Untch M, Marme F, Blohmer J, Jackisch C, GBG and AGO-B. Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). Eur J Cancer 2021; 156:138-148.
Aug 24, 2021Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)
Aug 24, 2021Eur J Cancer 2021; 156:138-148
Möbus Volker, Reinisch Mattea, Link Theresa, Sinn Bruno V, Janni Wolfgang, Denkert Carsten, Furlanetto Jenny, Engels Knut, Solbach Christine, Schmatloch Sabine, Rey Julia, Burchardi Nicole, Loibl Sibylle, Stickeler Elmar, Huober Jens, Lück Hans-Joachim, Ladda Ekkehart, Klare Peter, Schmidt Marcus, Schneeweiss Andreas, Grischke Eva-Maria, Wachsmann Grischa, Forstbauer Helmut, Untch Michael, Marme Frederik, Blohmer Jens-Uwe, Jackisch Christian, GBG and AGO-B
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial
Friedl T, Tesch H, Mahner S, Brucker S, Heinrich G, Häberle L, Fasching P, Beckmann M, Coleman R, Janni W, Schneeweiss A, Jückstock J, Fehm T, Müller V, Lichtenegger W, Blohmer J, Lorenz R, Forstbauer H, Fink V, Bekes I, Huober J, Rack B. Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial. JAMA Oncol 2021; 7:1149-1157.
Aug 1, 2021Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial
Aug 1, 2021JAMA Oncol 2021; 7:1149-1157
Friedl Thomas W P, Tesch Hans, Mahner Sven, Brucker Sara Y, Heinrich Georg, Häberle Lothar, Fasching Peter A, Beckmann Matthias W, Coleman Robert E, Janni Wolfgang, Schneeweiss Andreas, Jückstock Julia, Fehm Tanja, Müller Volkmar, Lichtenegger Werner, Blohmer Jens, Lorenz Ralf, Forstbauer Helmut, Fink Visnja, Bekes Inga, Huober Jens, Rack Brigitte
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial
De Gregorio A, Schneeweiss A, Tesch H, Mahner S, Brucker S, Blohmer J, Fehm T, Heinrich G, Lato K, Beckmann M, Rack B, Andergassen U, Bekes I, Fink V, Häberle L, Fasching P, Müller V, Schrader I, Lorenz R, Forstbauer H, Friedl T, Bauer E, De Gregorio N, Deniz M, Janni W. Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial. Breast Cancer Res 2020; 22:111.
Oct 23, 2020Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial
Oct 23, 2020Breast Cancer Res 2020; 22:111
De Gregorio Amelie, Schneeweiss Andreas, Tesch Hans, Mahner Sven, Brucker Sara Y, Blohmer Jens-Uwe, Fehm Tanja N, Heinrich Georg, Lato Krisztian, Beckmann Matthias W, Rack Brigitte, Andergassen Ulrich, Bekes Inga, Fink Visnja, Häberle Lothar, Fasching Peter A, Müller Volkmar, Schrader Iris, Lorenz Ralf, Forstbauer Helmut, Friedl Thomas W P, Bauer Emanuel, De Gregorio Nikolaus, Deniz Miriam, Janni Wolfgang
Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial
Bekes I, Janni W, Lato K, Kiechle M, Huober J, Dannecker C, Forstbauer H, Rack B, Harbeck N, Friedl T, Singer S, Eichler M, Fink V. Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial. Clin Breast Cancer 2020; 20:439-447.
Apr 6, 2020Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial
Apr 6, 2020Clin Breast Cancer 2020; 20:439-447
Bekes Inga, Janni Wolfgang, Lato Krisztian, Kiechle Marion, Huober Jens, Dannecker Christian, Forstbauer Helmut, Rack Brigitte, Harbeck Nadia, Friedl Thomas W P, Singer Susanne, Eichler Martin, Fink Visnja
Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial
Schwentner L, Janni W, Kiechle M, Härtl K, Weissenbacher T, Friedl T, Huober J, Scholz C, Wischnik A, Forstbauer H, Rack B, Eichler M, Singer S, Harbeck N, Fink V. Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial. Breast 2016; 27:69-77.
Apr 4, 2016Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial
Apr 4, 2016Breast 2016; 27:69-77
Schwentner Lukas, Janni Wolfgang, Kiechle Marion, Härtl Kristin, Weissenbacher Tobias, Friedl Thomas W P, Huober Jens, Scholz Christoph, Wischnik Arthur, Forstbauer Helmut, Rack Brigitte, Eichler Martin, Singer Susanne, Harbeck Nadia, Fink Visnja
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer
von Minckwitz G, Bauerfeind I, Clemens M, Schmidt M, Noeding S, Forstbauer H, Barinoff J, Belau A, Nekljudova V, Harbeck N, Lück H, Müller V, Kreienberg R, Möbus V, Schneeweiss A, Huober J, Thomssen C, Untch M, Jackisch C, Diel I, Elling D, Conrad B, Loibl S. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol 2013; 31:3531-9.
Aug 26, 2013German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer
Aug 26, 2013J Clin Oncol 2013; 31:3531-9
von Minckwitz Gunter, Bauerfeind Ingo, Clemens Michael, Schmidt Marcus, Noeding Stefanie, Forstbauer Helmut, Barinoff Jana, Belau Antje, Nekljudova Valentina, Harbeck Nadia, Lück Hans-Joachim, Müller Volkmar, Kreienberg Rolf, Möbus Volker, Schneeweiss Andreas, Huober Jens, Thomssen Christoph, Untch Michael, Jackisch Christian, Diel Ingo J, Elling Dirk, Conrad Bettina, Loibl Sibylle